Verrica Pharmaceuticals (VRCA) 24th Annual Needham Virtual Healthcare Conference summary

Company overview and product focus

• Dermatology-focused with in-office treatments; flagship product Ycanth treats molluscum contagiosum, a common childhood skin disorder with no prior FDA-approved options.

• Ycanth launched over a year ago; initial launch struggled, prompting late-2023 management and operational restructuring.

• Pipeline includes programs for common warts (in partnership with Torii Pharmaceutical) and late-stage development for basal cell carcinoma.

• U.S.-centric manufacturing and robust supply chain minimize tariff and supply risks.

Management and operational restructuring

• Restructuring cut expenses by about 50% and followed a $42 million capital raise in November 2023.

• Significant executive changes: new CEO, CFO, head of commercial, COO, and CMO with pharma development experience.

• Commercial team reduced from 85 to 35–40, focusing on high-demand territories and productivity per rep has increased.

Commercial strategy and market dynamics

• Shifted from a buy-and-bill model to a mix with specialty pharmacy, improving access and reducing financial risk for clinicians.

• Expanded coverage to both medical and pharmacy benefits, including Medicaid, to increase patient access.

• Flexible treatment initiation: some patients treated same day, others return after insurance adjudication; copay capped at $25.

• Awareness growing among clinicians and parents, supported by endorsements and targeted marketing.